**ORPHAN DISEASE CENTER**

**MILLION DOLLAR BIKE RIDE**

**COMPLEX LYMPHATIC ANOMALIES**

**YOUNG INVESTIGATOR AWARD**

**Cover Page**

PI Name:

PI Title:

PI Institution:

Mentor Name:

Mentor Title:

Mentor Institution:

Project Title:

Human Subjects Research:  Yes (Please attach IRB approval letter)  No

Animal Research:  Yes (Please attach IACUC approval letter)  No

Abstract (Up to 250 words):



**Checklist**

**CONTENT to be uploaded:**

**Cover Page/Checklist/Institutional Signature Page [PDF].**

**NIH-style Biosketch with Other Support of PI and Mentor** (5 pages max/PI, including Other Support). **[PDF]**

The PI must include accurate and complete information regarding all other sources of grant support (current and pending), including title, abstract, annual and total amount of grant, inclusive funding period, and percent effort.

**Detailed Budget and Justification.** **[combined into one PDF]**

Complete Excel budget sheet (to be provided). Describe justifications in a Word document. Award will be for one year. Proposed funding period: September 1, 2022 – August 31, 2023.

Total Budget is $25,000.

Institutions may opt to take up to 10% IDCs from their award totals. Awarded amounts will not exceed Award Total listed above.

|  |  |
| --- | --- |
| **Allowable direct costs** | **Unallowable costs** |
| * Salary for PI\* * Salary/stipend and related benefits for graduate student/postdoctoral fellow/technical support * Travel (up to $1500) * Laboratory supplies and other research expenses * IDCs of 10% are included in the total award amount * Equipment up to $5,000 (with prior approval from the ODC) | * Consultant costs * Tuition * Professional membership dues * Equipment >$5,000 * General office supplies institutional ---------administrative-charges (e.g., telephone, -- other electronic communication, IT ---------network, etc.) * Pre‐award charges * Any other expenses not directly related --to the project |

**\*** Beginning in May 2020, PI salary on all ODC Pilot awards will be applicable to the

National Institutes of Health Executive Level II Salary Cap. The current NIH Salary Cap

for the year 2022 is $203,700. For background and guidance, please refer to the

following link: <https://grants.nih.gov/grants/policy/salcap_summary.htm>

**Mentoring Plan** (1 page)

Describe the mentor’s role in the experimental design and execution. Describe the

plan for career development including strategies for mentorship in lymphatic

research and future research/funding.

**Mentoring Letter**

This letter is separate from the mentoring plan and should confirm the role and

activities outlined in the mentoring plan.

**Research Plan** (3 pages max)

* Specific aims, significance, and impact
* Approach
  + PI’s preliminary studies pertinent to the project.
  + A timeline, including the deliverables that will be generated, and the anticipated timeframe for each deliverable.
  + Anticipated potential problems and plans to address these issues.

All previous MDBR grant awardees must include a statement of outcomes including publications, patents and additional funding granted as a result of data generated from those grants. Specific aims must be different from those in previous applications.

**Project Disclosures and No Cost Extensions (NCE):**

* NCEs will be granted at the discretion of the ODC.
* Awardees will be limited to 1 NCE request for their award.
* Maximum NCE time awarded will be 6 months.
* NCEs will be granted after a formal request through [this form](https://upenn.co1.qualtrics.com/jfe/form/SV_5pCr7v7vjyNPKAu) found on the ODC website prior to the NCE deadline with adequate justification.
* If granted an NCE, you are still required to submit an interim scientific report 6 months into the duration of the original award period, regardless of your new project end date.
* In your letter of interest, you will be required to certify that you have identified qualified personnel to complete this project within the grant period **PRIOR** to the start date of the award. If you have not, you will be required to provide your plan to engage said personnel. Only under extenuating circumstances will personnel issues be considered for NCE requests.
* In your letter of interest, you will also be required to state whether or not you require access to reagents, cell lines, animal models, IRB/ethical board approvals, and/or equipment necessary to complete your work. If so, you will be required to describe your plan to gain access within the timeframe of this grant period.

**Grant Review Process:**

1. Grants will be reviewed for scientific content and relevance to the goals of the RFA.
2. Full applications proceed through a two-step review process. The first step includes external review and rating with an assessment of the strengths and weaknesses of each application based on the defined review criteria described below. During the second step, funding recommendations are determined based on an assessment of the reviewer scores and written comments. Final decision of funding will be made by Center Leadership.
3. Proposal Content and Review Criteria: The following criteria will be utilized in proposal review.

* **Project Proposal -** Is the proposed project of high scientific quality? Is the budget fully justified and reasonable in relation to the proposed project?
* **Background -** Is the fundamental objective of the study and hypothesis to be addressed clearly defined?
* **Scientific Approach -** Will the proposed specific aims answer the study hypothesis? Will the scientific approach effectively test and answer each specific aim? Are the study goals supported by existing data?
* **Clinical Impact -** Is the answer to the study hypothesis important to our ability to treat or reduce rare disorders/disease incidence and/or mortality? Will the proposed research lead to substantial advances and/or contribute to large leaps of understanding or knowledge that will contribute to reductions in disease incidence and/or mortality within the decade?
* **Research Significance -** Does the study address an important question that is not likely to be addressed without this funding? Does the proposed study offer a unique opportunity to explore an important issue and/or employ a novel approach to this disease research? Will the study outcomes advance our knowledge of this disease and/or contribute to changes in the focus of future research questions or the way we conduct research on this issue?
* **Investigator Qualifications –** Does the investigator hold a track record of outstanding accomplishment as evidenced by peer-reviewed publications and funding awards? Does the investigator have access to the resources and environment necessary to complete the study as outlined?

*Anonymous* reviewer feedback is shared upon the request of the applicant at the discretion of the Orphan Disease Center where appropriate.

**Confidentiality:**

The ODC Grant Programs are a confidential process and all content of the LOIs and Full Applications will be kept confidential by the ODC. In order to encourage sharing of new techniques and findings to advance science, after funding decisions are made, the ODC will share a non-confidential lay summary of the research proposals received (required with your letter of intent), including those that were not funded, with each participating funding organization. The ODC aims to respect and protect the integrity of your work, and thus will not release any proprietary information.

**Fund Disbursement:**

Funds will be issued through a cost reimbursement mechanism executed by purchase order from the University of Pennsylvania.  Details of invoicing schedules and reporting requirements will be made available upon award.  For additional information, please contact Samantha Charleston at [scharle@upenn.edu](mailto:scharle@upenn.edu) or 215-573-6822.

**A notice about COVID-19:** ODC will continue to monitor the global pandemic and will work with awardees to accommodate extensions that allow research aims to be completed safely in a mutually agreeable timeframe.

**ORPHAN DISEASE CENTER**

**MILLION DOLLAR BIKE RIDE**

**COMPLEX LYMPHATIC ANOMALIES**

**YOUNG INVESTIGATOR AWARD**

**INSTITUTIONAL SIGNATURE PAGE**

**Certification and Acceptance:**

We, the undersigned, certify that the statements contained in the attached grant application are true and complete to the best of our knowledge. We agree to conform to the policies and rules governing this award. We agree to openly share final data sets and observations with the full scientific community, and all reagents and/or research tools developed under support by this mechanism will be made accessible upon request. We understand that the University of Pennsylvania makes no claim to rights on these items or intellectual property other than for those faculty employed by the University of Pennsylvania. We understand that indirect costs are limited to 10% of direct costs.

**Principal Investigator:**

 **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Name (typed) Signature

Title:

Institution:

Department:

Address:

Phone:Fax:

E-mail:

**Project Mentor:**

 **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Name (typed) Signature

Title:

Institution:

Department:

Address:

Phone:Fax:

E-mail:

***Continued on next page***

**Institutional Official:**

 **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Name (typed) Signature

Title:

Institution:

Department:

Address:

Phone:Fax:

E-mail:

**ORPHAN DISEASE CENTER**

**MILLION DOLLAR BIKE RIDE**

**COMPLEX LYMPHATIC ANOMALIES**

**YOUNG INVESTIGATOR AWARD**

**Grant Program Award Terms**

1. Indirect Costs are limited to up to 10% of direct costs.
2. Awardees are required to provide updates concerning other support, resulting publications, and research activities, as requested.
3. An interim programmatic report is due ~March 1, 2023. A final report is due one month after the close of the project. Each two-page report must contain a synopsis of scientific progress, a list of resulting collaborations, publications and grants, a description of the relationship of the project to the goals of the related-disease research, a financial report, and a statement regarding unspent funds.
4. Awardees will receive payment on a quarterly cost reimbursement basis. Awardees must submit invoices with a breakdown of incurred costs to the grant over the previous three-month period. A template and invoicing details will be provided in the award agreement.
5. The following citation must be included in all publications: This work was supported in part by a research grant from the University of Pennsylvania Orphan Disease Center.
6. Appropriate citation of all collaborations must be included in all publications.
7. All final data sets and observations must be shared openly with the full scientific community, and all reagents and/or research tools developed under support by this mechanism must be made accessible upon request. The University of Pennsylvania makes no claim to rights on these items or intellectual property other than for those faculty employed by the University of Pennsylvania.

NOTE: Award terms are subject to change. If awarded, please refer to the grant award contract for actual project terms.

Continuation page template to be used for all content.

Continuation page template to be used for all content.